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Abstract 
Background: Escherichia coli causes over one third of the bacteraemia cases in England each year, 
and the incidence of these infections is increasing. 
Aim: To determine the underlying risk factors associated with E. coli bacteraemia.   
Methods: A three month enhanced sentinel surveillance study involving 35 National Health Service 
hospitals was undertaken in the winter of 2012/13 to collect risk factor information and further 
details on the underling source of infection to augment data already collected by the English 
national surveillance programme. Antimicrobial susceptibility results for E. coli isolated from blood 
and urine were also collected.  
Findings: A total of 1,731 cases of E. coli bacteraemia were. The urogenital tract was the most 
commonly reported source of infection (51.2% of cases) with prior treatment for a urinary tract 
infection being the largest independent effect associated with this infection source.  Half of all 
patients had prior healthcare exposure in the month prior to the bacteraemia with antimicrobial 
therapy and urinary catheterisation being reported in one third and one fifth of these patients. Prior 
healthcare exposure was associated with a higher proportion of antibiotic non-susceptibility in the 
blood culture isolates (P=0.001). 
Conclusion: Analysis of risk factors suggests potential community and hospital-related interventions 
particularly better use of urinary catheters and improved antibiotic management of urinary tract 
infections. As part of the latter strategy,  antibiotic resistance profiles need to be closely monitored 
to ensure treatment guidelines are up to date to limit inappropriate empiric therapy.  
 
Keywords: 
Urinary Tract Infection, Risk Factors, Healthcare Associated, Community 
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Introduction  
Voluntary surveillance identified  Escherichia coli as the leading cause of bacteraemia in England, 
with increasing incidence over time despite the overall incidence of bacteraemia being in decline1. In 
2015, 37,273 cases of E. coli bacteraemia were reported to the English mandatory surveillance 
programme2. Thirty-day all-cause mortality in England for this infection was recently estimated as 
18.2% (17.8-18.7%), equating to 5,220 deaths over a 12-month period3. Thus appropriately targeted 
interventions are required to reduce morbidity and mortality associated with E. coli bacteraemia. 
Whilst English mandatory surveillance of E. coli bacteraemia (initiated in 2011) allows better 
estimation of E. coli bacteraemia incidence than previously possible, detailed epidemiological 
information was needed to elucidate the reasons behind observed trends. 
Following a recommendation from ƚŚĞh<ŐŽǀĞƌŶŵĞŶƚ ?ƐĚǀŝƐŽƌǇŽŵŵŝƚƚĞĞŽŶ
Antimicrobial Resistance and Healthcare Associated Infection (ARHAI), a sentinel surveillance 
scheme was initiated  to augment existing mandatory surveillance.4 The sentinel programme aimed 
to gather more detailed risk factor information for patients in the hospital and community setting. 
Specific data collected included antibiotic consumption, use of urinary catheters, indwelling vascular 
access and other devices, and invasive procedures prior to the bacteraemia. Additionally we aimed 
to gather detailed information regarding the clinically identified focus or cause of bacteraemia and 
antibiotic susceptibility data for the E. coli blood and urine cultures.  
 
Methods 
Study design 
The sentinel study ran in participating English NHS Trusts (hospitals under the same 
management board) over the winter of 2012/13. The study was powered to detect with 95% 
confidence the prevalence of an underlying infection focus or risk factor with a true frequency of at 
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least 10%, based on estimates of the prevalence of the second commonest focus (hepatobiliary) 
reported via mandatory surveillance.5 As the sampling strategy was clustered (by NHS Trust and not 
patient) a design effect was included. This equated to a sample size of 2,625 E. coli bacteraemia 
cases; we therefore aimed to recruit 40 Trusts with data collection running over 3 months. 
Participating Trusts were selected using simple random sampling. Additionally, two specialist cancer 
Trusts and six interested Trusts were included post-hoc.  
Cases from the sentinel study were linked to mandatory E. coli bacteraemia reports (linked 
using NHS number, a unique personal identifier) to obtain further patient and specimen information 
and to voluntary laboratory reports 6 (linked using a combination of available personal identifiers 
[NHS number, hospital number, date of birth, gender, encrypted surname]) to obtain antibiotic 
susceptibility data for both E. coli blood culture (if  not reported by sentinel sites) and urine cultures, 
one month and one year before the date of the blood culture. Duplicate entries for the same patient 
within the same episode (considered as 14 days), were removed from analysis with data relating to 
the earliest specimen retained. This study focused on E. coli bacteraemia and for cases of 
polymicrobial bacteraemia only information pertaining to the E. coli isolate was retained.    
Data items relating to healthcare exposure prior to the bacteraemia were collected. 
Specifically, in the prior three days: indwelling vascular access devices (in situ or removed), including 
the type of intravascular device; in the prior 7 days: urinary catheterisation (in situ, inserted, 
removed or manipulated), including the type of catheter, insertion method and primary indication 
for catheterisation; in the prior 4 weeks: other devices (in situ or removed), including the type of 
device and date of insertion; other procedures, including the type and date of procedure; and 
antimicrobial chemotherapy, including antibiotic name(s), indication and the treatment area. 
Patients with more than one healthcare exposure reported or more than one occurrence of a 
specific healthcare exposure were included in the study. Prior healthcare exposure in either the 
community or hospital ŝŶƚŚĞ ?ǁĞĞŬƐĂŶĚ ?ǁĞĞŬďĞĨŽƌĞďĂĐƚĞƌĂĞŵŝĂǁĂƐĐĂƚĞŐŽƌŝƐĞĚĂƐ ?zĞƐ ?ŝĨĂƚ
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ůĞĂƐƚŽŶĞŽĨƚŚĞĂďŽǀĞĚĂƚĂŝƚĞŵƐǁĞƌĞƐĞůĞĐƚĞĚĂƐ ?zĞƐ ? or as  ?EŽ ?ŝĨĂůůŽĨƚŚĞĂďŽǀĞŝƚĞŵƐǁĞƌĞ
ƐĞůĞĐƚĞĚĂƐ ?EŽ ?; ŽƚŚĞƌǁŝƐĞŝƚǁĂƐĐŽĚĞĚĂƐ ?EŽƚŬŶŽǁŶ ? ?/ŶĂĚĚŝƚŝŽŶƚŽthese data item, the 
primary focus or reason for the bacteraemia was collected. More detail on data collection can be 
found in Supplementary Information 1.  
Time of bacteraemia onset based on the days between hospital admission and the taking of 
a positive blood culture was categorised as follows: on or day after admission (a proxy for 
community-onset infection); 2-6 days after admission (proxy for early healthcare-onset infection); 7 
days or more after admission (proxy for late healthcare-onset infection); from a non-admitted 
patient.  
Information on susceptibility of the E. coli blood culture and urine isolates to ciprofloxacin, 
trimethoprim, co-amoxiclav, third-generation cephalosporins (cefotaxime/ceftazidime), 
carbapenems (imipenem/meropenem), gentamicin, nitrofurantoin and piperacillin/tazobactam was 
ascertained using laboratory data reported via the national voluntary surveillance system. The 
presence of a urine culture in the linked laboratory dataset was taken as a proxy for urinary tract 
infection (UTI) in the month or year prior to the E. coli bacteraemia. Combined susceptibility for 
ďůŽŽĚĐƵůƚƵƌĞƐ ?ƵƐŝŶŐƚŚĞĂďŽǀĞĂŶƚŝďŝŽƚŝĐƐ ?ǁĂƐĐĂƚĞŐŽƌŝƐĞĚĂƐ ? ?ŶŽŶ-ƐƵƐĐĞƉƚŝďůĞ ?ŝĨƚŚĞďůŽŽĚ
culture was recorded as non-susceptible to at least one of the aforementioned antibiotics; and 
 ?ƐƵƐĐĞƉƚŝďůĞ ?ŝĨƚŚĞďůŽŽĚĐƵůƚƵƌĞǁĂƐƌĞĐŽƌĚĞĚĂƐƐƵƐĐĞƉƚŝďůĞto all of the aforementioned 
antibiotics.  
Statistical analysis 
General associations between two variables were examined using the Chi2 test. Multivariable logistic 
regression was used to estimate the independent effects of prior UTI, prior treatment of a urogenital 
tract infection and urinary catheterisation, on having a urogenital tract focus of bacteraemia, 
controlled for the effects of age, gender, (both of which were considered a priori confounders thus 
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automatically included in the model) treatment specialty and timing of bacteraemia onset. Only the 
presence of a UTI in the month prior to the bacteraemia was used in the model as it was considered 
more directly relevant than a UTI one year prior. A random effects term was used to control for 
clustering by reporting Trust.  Variables that were not significant in the final model were omitted, 
even if the crude odds ratios showed a significant effect. All data management and analyses were 
performed using Stata 13.0.7 
 
Results 
Thirty-five NHS acute Trusts submitted data to the sentinel programme, representing 1,731 cases of 
E. coli bacteraemia. Thirty-seven cases could not be linked to the mandatory surveillance dataset 
and were excluded from analysis and six cases were removed as within-episode duplicates. We 
achieved 90% power in our estimate of a risk factor or focus with a frequency of 10%. Distributions 
of cases from this sentinel study compared to the national mandatory data by patient sex or age and 
by time of onset or focus of bacteraemia were not statistically distinct P>0.05 (data not shown).  
Description of the study participants  
Half of the bacteraemias (n= 833; 49.3%) were in patients aged >75 years, and around half 
were in women (n=901; 53.4%) (Table 1). Over two-thirds of patients had a positive blood culture 
taken 0-1 day after admission (n=1,153; 68.3%).  The underlying infection focus was reported as the 
 ?ƵƌŽŐĞŶŝƚĂůƚƌĂĐƚ ?ŝŶ ? ? ? ?A? ?ŶA? ? ? ? ?ŽĨƉĂƚŝĞŶƚƐ ?dŚĞŶĞǆƚŵŽƐƚfrequent ĨŽĐŝǁĞƌĞ ?ŚĞƉĂƚŽďŝůŝĂƌǇ ?
 ? ? ? ? ?A? ?ŶA? ? ? ? ? ?ĂŶĚ ?ƵŶŬŶŽǁŶ ? ? ? ? ? ?A? ?ŶA? ? ? ? ? ? 
Healthcare exposure prior to the bacteraemia  
Half (n=930) of the patients had a healthcare exposure, as defined in the Methods section, in 
the four weeks prior to the bacteraemia and one third (n=584) had a healthcare exposure in the 
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week prior to the bacteraemia.  The percentage of patients with prior healthcare exposure increased 
as the time of bacteraemia onset after hospital admission increased (Figure 1). Of the patients 
diagnosed 0-1 day after admission, 46.7% (n=538) had a healthcare exposure in the month prior to 
the bacteraemia, increasing to 85.4% (n=251) in patients in hospital for A?7 days prior to the 
bacteraemia reflecting the increased opportunity of  healthcare exposure for admitted patients as 
well as potentially more comorbidities. Stratification by age showed some variation in prior 
healthcare exposure four weeks prior to the bacteraemia, with 26.9% (n=7) of 0-1 year olds, 54.3% 
(n=95) of 1-44 year olds, 57.5% (n=651) of 45-84 year olds and 49.9% (n=177) of patients 85 years or 
more having had a prior healthcare exposure (details not shown). 
Antimicrobial therapy was the most commonly reported prior healthcare exposure in one 
third (n=546) of patients (Table 1);-of these 546 patients 58.4% (n=319) received one antibiotic, 
23.1% (n=126) received two and the remaining 101 received three or more . Seventy-nine percent 
(721/907) of the antibiotic prescriptions were for treatment of infection.Treatment for infection of 
the urogenital tract was most commonly reported (n=229; 31.8%), followed by treatment of the 
respiratory tract (n=123; 17.1%).  For patients treated for urogenital tract infection, trimethoprim 
and co-amoxiclav were most commonly prescribed (n= 50 [21.8%] and n= 47 [20.5%], respectively). 
Fourteen percent (125/907) of prescriptions were for medical or surgical prophylaxis; where the site 
was reported (n=115), 26.1% (n=30) of prescriptions were for a genito-urinary site. Twelve of these 
patients were catheterised in the three days prior to the bacteraemia. It was not possible to 
determine if these patients were also treated for a UTI as treatment and prophylaxis were mutually 
exclusive options.   
Twenty-two percent of patients (n=373) had an indwelling intravascular device that either 
remained in situ at the onset of the bacteraemia, or had been removed within the 3 days prior to the 
bacteraemia (Table 1). Of these patients, 88.2% (n=329) had one indwelling intravascular device and 
8.0% (n=30) had two with the remainder having between three and six. Where reported (n=444), the 
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most common catheter types were peripheral (41.6%; n=184), and central venous catheters (11.8%; 
n=52).  
Twenty-one percent of patients (n=354) either had a urinary catheter in place at the time of 
the bacteraemia, or  had one inserted, removed or manipulated in the 7 days prior to the 
bacteraemia (Table 1); of these, 96.9% (n=343) were catheterised just once.  Where reported 
(92.7%; n=328) urinary retention (27.1%; n=89) and fluid balance (21.6%; n=71) were the primary 
reasons for catheterisation. Eleven percent (n=36) of patients had a catheter inserted for 
incontinence. The reason for catheterisation  was unknown in 19.2% (n=63) of instances. The 
primary insertion type was urethral (91.8%; n=302). Long term  ?ŝŶƐŝƚƵA? ? ?ĚĂǇƐ ? and short term (in 
situ <28 days) catheters predominated (41.3%; n=152 and 38.3%; n=141, respectively), the 
remaining 20% were reported as temporary catheters. Among the patients whose bacteraemia was 
ĚĞƚĞĐƚĞĚA? ?ĚĂǇƐĂĨƚĞƌŚŽƐƉŝƚĂůĂĚŵŝƐƐŝŽŶ ?ŶA? ? ? ? ? ? ? ? ?A? ?ŶA   ? ? ?ŚĂĚbeen subject to urinary 
catheterisation in the 7 days before bacteraemia. The equivalent figure for patients with a 
bacteraemia detected 2-6 days after admission was 36.4% (n=47/129) and for those detected on 
admission it was 15.4% (n=178/1,153).  
Twelve and seven percent (n=209 and n= 123, respectively) of patients had another 
procedure or device in the four weeks before bacteraemia. Of the available procedure categories, 
 ?ŽƚŚĞƌ ?ǁĂƐŵŽƐƚĨƌĞƋƵĞŶƚůǇƐĞůĞĐƚĞĚ ? ? ? ? ?A? ? ?ŽĨǁŚŝĐŚĂƉƉƌŽǆŝŵĂƚĞůǇŚĂůĨǁĞƌĞƐƵƌŐŝĐĂůƉƌŽĐĞĚƵƌĞƐ ? 
Patients with an underlying urinary focus of bacteraemia 
Six-hundred and ninety (79.8%) of the 865 patients where the underlying infection focus was 
ƌĞƉŽƌƚĞĚĂƐƚŚĞ ?ƵƌŽŐĞŶŝƚĂůƚƌĂĐƚ ?ǁĞƌĞƌĞĐŽƌĚĞĚĂƐŚĂǀŝŶŐĂhd/ ?ŵŽŶŐƐƚƚŚŽƐĞƉĂƚŝĞŶƚƐǁŝƚŚĂ
urogenital tract focus where the date of infection onset was recorded (n=510), 48.4% (n=248) had 
the blood culture taken on the day of onset, while for a further 214 patients (41.8%) the onset of 
infection occurred up to 7 days before the positive blood culture was taken.  Where the urogenital 
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infection was reported as catheter-, procedure-, or device-related (n=171), 84.2% (n=144) were 
related to a urinary catheter, 12.3% (n=21) to a procedure and the remainder (3.5%; n=6) to a 
device. Where information on prior UTIs was reported, two thirds of patients (62.4% n=176/282) 
had at least one prior UTI.. Of patients with a urogenital tract focus with at least one antibiotic 
prescribed in the four weeks prior to bacteraemia, 51.6% (145/281) of antibiotics were prescribed 
for treatment of urogenital system-associated infection. Where reported co-amoxiclav (23.1%; 
n=29/212) and trimethoprim (22.2%; n=47) were most commonly prescribed, whilst 9.9% (n=21) 
were prescribed nitrofurantoin.  
 
Regression analysis of factors associated with urinary tract focus of infection 
 The largest independent ƌŝƐŬĨĂĐƚŽƌĨŽƌĂďĂĐƚĞƌĂĞŵŝĂ ?ƐƵŶĚĞƌůǇŝŶŐĨŽĐƵƐďĞŝŶŐ the 
urogenital tract was prior treatment for urogenital tract infection within 4 weeks of the bacteraemia 
onset: adjusted OR (aOR) 10.7 (95% confidence interval (CI): 6.3-18.1) (Table 2). Having had a UTI in 
the month prior to bacteraemia increased the odds of urogenital tract-related bacteraemia 5-fold 
(aOR 5.4; 95% CI 3.6- ? ? ? ? ?,ĂǀŝŶŐĂĐĂƚŚĞƚĞƌŝŶƐĞƌƚĞĚĨŽƌŝŶĐŽŶƚŝŶĞŶĐĞ ?ǀĞƌƐƵƐ ?ŽƚŚĞƌ ? ?ĂŶĚ surgical 
specialty (versus medical specialty) also increased the odds of a urogenital tract focus (aOR 5.2; 95% 
CI: 1.5-18.1 and aOR 4.3; 95% CI 2.0-9.3, respectively). Several factors were associated with a 
reduction in the odds of a urogenital tract focus of infection including male gender, unknown 
presence of catheter, general specialty and bacteraemia detected 2-6 days or Ӌ7 days post 
admission.  
Antibiotic susceptibility 
Where tested, the highest levels of antibiotic non-susceptibility among isolates from blood 
were to co-amoxiclav (43.0% [n=511/1,188]) or trimethoprim (40.5% [n=317/783]) (Figure 2). 
Ciprofloxacin non-susceptibility was seen in 17% of tested isolates (n=187/1,100). Carbapenem non-
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susceptibility was only observed in two isolates out of 1,060 tested. There was an association 
between timing of bacteraemia onset and co-amoxiclav (p=0.027) and piperacillin/tazobactam 
(p=0.008) susceptibilities, both of which showed a greater proportion of non-susceptible isolates 
from patients with  bacteraemia detected 2 or more days after hospital admission (Table 3). 
Ciprofloxacin (p=0.02) and trimethoprim (p<0.001) non-susceptibility were associated with different 
foci of infection with a greater percentage of isolates non-susceptible ciprofloxacin found in patients 
with  ?ƉŶĞƵŵŽŶŝĂ ?reported as the underlying infection focus (23.7%; 9/38), whilst trimethoprim 
non-susceptibility was most commonly observed in patients with an underlying urogenital tract 
focus (48.1%; 198/412) (Table 4).  There was an association between antibiotic non-susceptibility of 
blood culture isolates and healthcare exposure in the four weeks prior to the bacteraemia (P=0.001), 
with 60.9% (n=406/667) of isolates from patients with prior healthcare exposure showing non-
susceptibility to at least one of the antibiotics tested versus 50.7% (n=165/330) of isolates without a 
prior healthcare exposure (data not shown). Antibiotic non-susceptibility was also associated with 
antibiotic exposure in the four weeks prior to bacteraemia (P<0.001), the rates of  non-susceptibility 
being 66.5% (n=262/394) and 51.4% (n=244/475), in those with and without prior antibiotic 
exposure respectively (data not shown).      
Urine cultures with antibiotic susceptibilities one year and four weeks prior to the E. coli 
bacteraemia were identified for 340 (20.1%) and 230 (13.6%) patients, respectively. The highest 
levels of non-susceptibility in isolates from urine at both time points were for trimethoprim (47.7% 
[n=162/340] at one year and 46.3% [n=106/229] at four weeks (not shown). Co-amoxiclav non-
susceptibility was also common at around 30% at both time points. Ciprofloxacin non-susceptibility 
was seen in 20.4% (n=47/231) and 15.5% (n=23/148) of urinary isolates in the year and four weeks 
prior to the bacteraemia. The levels of non-susceptibility to third-generation cephalosporins at the 
same time points were 21.3% (29/136) and 13.8% (12/87), respectively. Non-susceptibility to 
piperacillin/tazobactam was c. 23% (22.1% (28/127) at one year and 24.4% (20/82) at four weeks 
prior to the bacteraemia. Non-susceptibility to nitrofurantoin was low, being reported in 6.9% 
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(22/321) of isolates at one year and 4.6% (10/216) at one month.  Only oŶĞƉĂƚŝĞŶƚ ?ƐŝŶĨĞĐƚŝŽŶǁĂƐ
caused by E. coli non-susceptible to carbapenems at both time points.  
Where antibiograms were available for both urine and blood isoaltes from the same patient, 
there was a significant association between non-susceptibility in urine and the subsequent blood 
culture for each of the antibiotics examined, the association being stronger for isolates taken up to 
four weeks prior to the bacteraemia compared with the association at one year (data not shown).    
 
Discussion  
While large declines in infections such as methicillin-resistant Staphylococcus aureus 
bacteraemia were concomitant with healthcare-based interventions (e.g. intravascular device-
related care bundles; screening/decolonisation of high risk patients), E. coli bacteraemia is 
frequently considered a community-associated infection with lesser scope for reducing incidence.8-10 
All potential areas for  reducing E. coli bacteraemia incidence do, however, need to be investigated 
given the high burden of this infection (37,273 cases reported for 20152) as even small reductions in 
incidence could  equate to thousands of patients a year.  The data presented here highlight potential 
interventions for reducing E. coli bacteraemia incidence, such as improved urinary catheter care and 
UTI diagnosis and management.  
Several of our findings suggest treatment failure in UTIs is an important risk factor for the 
development of E. coli bacteraemia. Hence prompt diagnosis and appropriate treatment of UTIs, the 
commonest underling focus of E. coli bacteraemia identified here and elsewhere,11,12 with 
antibiotics to which the organism is susceptible are key in limiting progression from UTI to 
bacteraemia and severe sepsis. Antibiotic therapy in the four weeks before bacteraemia was the 
most commonly reported healthcare exposure (one third of patients), and of these patients almost 
one third were prescribed antibiotics for treatment of a genito-urinary infection. Notably the most 
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commonly prescribed antibiotics for these patients were trimethoprim and co-amoxiclav, where 
non-susceptibility in urine isolates was common (around 47% and 30%).  Furthermore, trimethoprim 
non-susceptibility was common (40.5%) in E. coli blood isolates. This may reflect prior trimethoprim 
ĞǆƉŽƐƵƌĞŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨƚŚĞƉĂƚŝĞŶƚ ?Ɛhd/ǁŝƚŚƐƵďƐĞƋƵĞŶƚƐĞůĞĐƚŝŽŶŽĨƌĞƐŝƐƚĂŶƚƐƚƌĂŝŶƐůĞĂĚŝŶŐ
to treatment failure and progression to bacteraemia, or UTI caused by uropathogenic strains already 
resistant to trimethoprim. These findings are concerning in relation to trimethoprim as this antibiotic 
typically dominated  first-line treatment recommendations for uncomplicated UTI in primary care,13 
and thus is commonly prescribed,14 as supported by our findings. However it is reassuring that 
recent guidelines now advocate nitrofurantoin therapy with trimethoprim use dependant on local 
resistance patterns.15 This reiterates that guidelines for empiric UTI therapy need constant review 
and updating. Whilst nitrofurantoin non-susceptibility was lower at around 5-7%, trends need to be 
monitored given its increasing importance in empiric UTI therapy. Non-susceptibility to third-
generation cephalosporins in urine was higher than typically seen in E. coli blood isolates, especially 
in patients with a history of UTIs within a year  before bacteraemia; these  patients may represent 
UTI treatment failures or those carrying multi-drug resistant, but not especially virulent, isolates. 
Furthermore, the association between resistance in urine before bacteraemia is consistent with a 
recent meta-analysis showing that  prior antibiotic exposure increased the odds of antibiotic non-
susceptibility.16 Whilst ciprofloxacin, third-generation cephalosporins, gentamicin and carbapenems 
are less frequent first-line therapies for  UTIs,14 they are important for treating more severe 
infections, thus  non-susceptibility trends  should be monitored.  
Prior healthcare exposure, regardless of whether it was one week or month prior to the 
bacteraemia case, primarily equated to antibiotic prescribing and maybe an important factor for 
subsequent non-susceptible E. coli bacteraemia. This highlights patient groups with E. coli 
bacteraemia who may be more likely to have a non-susceptible infection and justifies the current 
focus on antibiotic prescribing and antimicrobial resistance. We noted a general trend for increased 
non-susceptibility with healthcare-onset bacteraemia cases, however this was only significant for co-
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amoxiclav and piperacillin/tazobactam. This is most likely due to these being common first-line 
therapy for patients presenting at hospital with an infection and where these infections 
subsequently progress to a bacteraemia resistant isolates will be selected for. A larger study may 
have also identified significant associations for other antibiotics.  
Regression analysis somewhat predictably identified prior urogenital tract infection 
treatment and having a UTI in the month prior to the bacteraemia were  the most important risk 
factors for the development of a (presumed) urogenital tract focus bacteraemia, increasing  the odds 
of a urogenital tract focus  10.7 and 5.4 fold, respectively. We hypothesise that patients with urine 
samples sent for antimicrobial testing would more likely have experienced treatment failure  or had 
a complicated UTI, as most uncomplicated UTIs are typically treated empirically in  primary care.17 
Furthermore, three quarters of patients with a urogenital tract focus had their bacteraemia detected 
on admission. This implies either a failure in diagnosis and treatment of UTI in the community or 
patients presenting directly to the hospital with bacteraemia who have not visited their primary care 
physician for treatment of their symptoms. Greater awareness of the patient groups at risk of UTIs 
developing into bacteraemia in the community and hospital could reduce treatment failure or 
unrecognised complicated UTIs progressing to bacteraemia, through for example enhanced 
monitoring of patients with suspected UTI and prompt intervention when empirical treatment fails. 
Mid-stream urine sampling of all patients with symptomatic UTI, or where other wise indicated in 
the guidence for susceptibility screening would also allow appropriate antibiotic therapy to be 
prescribed. 17  Further studies are warranted to gain a better understanding of who these patients 
are and what the potential intervention opportunities may be. Near patient testing for antimicrobial 
resistance may be a future option to improve management. Furthermore reduction of UTI incidence 
would limit the largest underlying focus of E. coli bacteraemia; studies are required to understand 
how this can be achieved.   
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Urinary catheter use was also identified as an important risk factor. We found that 21% of 
patients had a urinary catheter inserted, removed or manipulated in the week before bacteraemia; 
144 reported bacteraemias were likely related to a urinary catheter in the study. Urinary catheters 
inserted for incontinence were associated with a 5.2-fold increase in the risk of a urinary focus of 
infection.  Whilst incontinence and the other main reasons for catheterisation (urinary retention and 
fluid balance) could be considered appropriate indications,18 without more detailed patient medical 
history  it is not possible to determine whether each catheter was appropriately used. Additionally, it 
is concerning that for one in five catheterised patients the indication for catheterisation was not 
known/recorded, indicating a lack of optimised patient management , possibly increasing the risk of 
complications. Furthermore, almost half of the catheterised patients had a long-term catheter. 
Although this may have been appropriately indicated, it nonetheless increases the risk of infection 
compared to short-term catheters as the risk of infection developing from catheters increases with 
catheterisation duration.19 Periodic review of patients with long term catheters is advised 20 and 
should be followed. Further research is required to determine if suprapubic versus urethral long 
term catheters would present a lower infection risk both of which may reduce urinary catheter-
related infections. 
There is considerable literature highlighting high levels of catheter use in healthcare,14,21,22 
with evidence for a large proportion of such usage being inappropriate and/or poorly monitored.23,24  
We identified that the percentage of patients with a urinary catheter increased from 15.4% in those 
diagnosed around admission to 40.1% in those diagnŽƐĞĚA? ?ĚĂǇƐĂĨƚĞƌĂĚŵŝƐƐŝŽŶ ?dŚŝƐŝĚĞŶƚŝĨŝĞƐ
the importance of appropriate catheter care in the community as well as close monitoring in 
hospitalised patients. The latter represent a patient group where device-related hospital-based 
interventions could be targeted to reduce E. coli bacteraemia incidence, although it is worth noting 
that the present data is unable to identify which patients may be catheterised as part of the sepsis 
pathway for monitoring of urinary output. 
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Urinary catheter use is associated with an increased risk of complications, notably catheter-
associated UTI.22,25,26 Given the urinary tract is the predominant underlying focus of E. coli 
bacteraemia, appropriate catheter use and management are obvious interventions, particularly 
when the catheter is used solely for incontinence where non-invasive treatment options exist. As 
with the management of UTIs, any such intervention must be targeted at the community and 
hospital setting as many catheterised patients reside in the former 21 supported by the data here.  
These sentinel data are representative of the national picture of E. coli bacteraemia, based 
on comparisons of age, gender, timing of bacteraemia onset and underlying focus of infection. 
Despite a smaller sample size than intended, the power of the sentinel study was 90% to detect a 
risk factor or focus with a frequency of 10%.  There are, however, several limitations to the present 
study. Our study has only collected information on patients with E.coli bacteraemia therefore it is 
not possible to compare the population with and without infection, nor to estimate the impact of 
interventions on reducing E.coli bacteraemia incidence. The susceptibility results relate to 
antimicrobials tested which were not necessarily those received by the patient. Thus, it is not 
possible to determine the effects of antimicrobial exposure for the treatment of UTI on subsequent 
non-susceptibility in blood cultures. Additionally antimicrobial testing practices vary by laboratory 
and some antibiotics are less frequently tested which may impact on the linked urine antimicrobial 
results. Robust information on the management and treatment of prior UTIs and catheter use would 
provide further resolution on specific risk factors.  
It is clear from this study that E. coli bacteraemia is often secondary to an earlier UTI. 
Therefore, prevention of UTIs, particularly in the elderly, will reduce bacteraemia developing.  We 
have highlighted potential interventions and further research  to reduce the incidence of E. coli 
bacteraemia in England: 1) close monitoring and effective treatment of patients with suspected UTI; 
2) awareness of local antibiotic resistance profiles with early recognition of UTI treatment failure 
with prompt initiation of effective antimicrobial therapy; 3) early identification of suspected 
16 
 
bacteraemia secondary to UTI, primarily in the community; 4) appropriate use and management of 
urinary catheters in the hospital and community with monitoring for signs of infection; 5) further 
research on UTI incidence in England, infection rates in suprapubic versus long term catheters, and 
antibiotic consumption patterns.  
Whilst interventions targeted at the community setting may be harder to implement and 
monitor than hospital-based interventions, this should not be a reason for not trying, given the high 
burden of E. coli bacteraemia.  
 
    
 
 
 
17 
 
 
Transparency declaration 
This work was funded in its entirety by Public Health England.   
 
MHW has received: consulting fees from Actelion, Astellas, Astra-Zeneca, Bayer, Cerexa, Cubist, 
Durata, The Medicines Company, MedImmune, Merck, Motif Biosciences, Nabriva, Optimer, Paratek, 
Pfizer, Roche, Sanofi-Pasteur, Seres, Summit, and Synthetic Biologics; lecture fees from Abbott, 
Alere, Astellas, Astra-Zeneca, Pfizer & Roche; and grant support from Abbott, Actelion, Astellas, 
bioMerieux, Cubist, Da Volterra, Merck, Paratek, Pfizer, Sanofi-Pasteur and Summit. SH is affiliated 
with the National Institute for Health Research Health Protection Research Units (NIHR HPRU) in 
Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London and 
University of Oxford in partnership with Public Health England (PHE). The other authors had nothing 
to disclose. The views expressed in this article are those of the authors and not necessarily shared by 
their organisations or affiliates. 
 
 
JKA lead on the scientific writing and analysis, RJH and APJ edited initial drafts and gave feedback on 
early analysis, JKA, ES, SH, MK, MHW, APJ and RJH designed the surveillance programme and 
associated questionnaire. RG performed the linkage work required for the antibiotic susceptibility 
data and the identification of urinary cases. All authors commented on the final edits of the 
manuscript. 
 
 
 
Acknowledgements 
18 
 
The E. coli bacteraemia sentinel surveillance group comprised of the following NHS acute Trusts and 
collaborators who we thank for participating in the study:  
Aintree University Hospitals, Dr Rachel A Sen; Barts & the London, Dr Albert Mifsud; 
Buckinghamshire Healthcare, ƌ:ĞĂŶK ?ƌŝƐcoll; Cambridge University Hospitals, Dr Nick 
Brown/Cheryl Trundle; County Durham & Darlington, Dr David Allison; Croydon Health Services, Dr 
Mary Twagira; Derby Hospitals, Dr Gnanarajah; East & North Hertfordshire, Dr Fatih Awad-El Kariem; 
East Cheshire, Dr Rajesh Rajendran; East Sussex Healthcare, Dr S Umashankar; Gateshead Health, Dr 
Glenda Horne; Homerton University Hospital, Dr Alleyna Claxton; Lancashire Teaching Hospitals, Dr 
John Cheesbrough; Leeds Teaching Hospitals, Dr Andrew Kirby; Luton & Dunstable Hospital, Dr 
Rohinton Mulla; Mid Essex Hospital Services, Dr Louise Teare; Newham University Hospital, Dr Caryn 
Rosmarin; North West London Hospitals, Dr G Gopal Rao; Northern Devon Healthcare, Dr David 
Richards; Nottingham University Hospitals, Dr Tim Boswell; Oxford University Hospitals, Dr Ian 
ŽǁůĞƌ ?>ŝůůǇK ?ŽŶŶŽƌ; Plymouth Hospitals, Dr Peter Jenks; Portsmouth Hospitals, Dr Sarah Wyllie; 
Royal Berkshire, Dr Nilangi Virgincar; Royal Free Hampstead, Dr Susan Hopkins; South London 
Healthcare, Dr Martino Dallantonia; South Tyneside, Dr Alan Rodgers/Dr Richard Ellis; Southport & 
Ormskirk Hospital, Dr Judith Bowley/Martin Kiernan; Surrey & Sussex Healthcare, Dr Karen Knox; The 
Royal Marsden, Dr Unell Riley; The Whittington Hospital, Dr Michael Kelsey; University College 
London Hospitals, Dr Peter Wilson/Dr Nan Shetty; University Hospital of North Staffordshire, Dr 
Jeorge Orendi; University Hospitals of Morecambe Bay, Dr Monika Pasztor 
tĞǁŽƵůĚĂůƐŽůŝŬĞƚŽĂĐŬŶŽǁůĞĚŐĞ ?ƚŚĞh<ŐŽǀĞƌŶŵĞŶƚ ?ƐĚǀŝƐŽƌǇŽŵŵŝƚƚĞe on 
Antimicrobial Resistance and Healthcare Associated Infection  E. coli sub-group (Martin Kiernan; Dr 
Cliodna McNulty; Professor Peter Hawkey; Professor Heather Loveday; Dr Carol Pellowe; Dr Russell 
Hope; Ann Moore; Dr Stuart Bruce; Catherine Williams; Zara Head; Dr Ruth Milton; Jennie Wilson) 
for their support for the sentinel study; Dean Ironmonger for technical support in the development 
of the software; and Sobia Wasti and Angela Falola for assisting in recruitment of the sentinel sites. 
19 
 
 
 
  
20 
 
 
Reference List 
 
 1.  Wilson J, Elgohari S, Livermore DM, Cookson B, Johnson A, Lamagni TL, et al. Trends among 
pathogens reported as causing bacteraemia in England, 2004-2008. Clin Microbiol Infect 2010 
May 18;17;3:451-8. 
 2.  Public Health England. Escherichia coli (E. coli) bacteraemia: monthly data by NHS acute Trust. 
GOV UK 2016 [cited 2016 May 29]; 
 3.  Abernethy JK, Johnson AP, Guy R, Hinton N, Sheridan EA, Hope RJ. Thirty day all-cause 
mortality in patients with Escherichia coli bacteraemia in England. Clin Microbiol Infect 2015 
Mar;21;3:251-8. 
 4.  Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infection. 
Advisory Committee on Antimicrobial Resistance and Healthcare-Associated Infection (ARHAI). 
Twentieth meeting on 21st September 2012. Meeting Minutes. National Archives 2012 [cited 
2015 Aug 27];Available from: URL: 
http://webarchive.nationalarchives.gov.uk/20130402145952/http://media.dh.gov.uk/network
/261/files/2012/10/arhai-minutes-21-september-2012.pdf 
 5.  Public Health England. Annual Epidemiological Commentary: Mandatory MRSA, MSSA and E. 
coli bacteraemia and C. difficile infection data, 2013/14.  10-6-2014. London, Public Health 
England.  
 6.  Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and 
antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: 
trend analysis. BMJ 2000 Jan 22;320;7229:213-6. 
 7.  StataCorp College StationTX: StataCorp LP. Stata Statistical Software: Release 12.  2011.  
 8.  Melzer M, Welch C. Is Escherichia coli bacteraemia preventable? Lancet Infect Dis 2012 
Feb;12;2:103-4. 
 9.  Underwood J, Klein JL, Newsholme W. Escherichia coli bacteraemia: how preventable is it? J 
Hosp Infect 2011 Dec;79;4:364-5. 
 10.  Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A, et al. Mandatory surveillance 
of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 
years. J Antimicrob Chemother 2012 Apr;67;4:802-9. 
 11.  Marschall J, Zhang L, Foxman B, Warren DK, Henderson JP. Both host and pathogen factors 
predispose to Escherichia coli urinary-source bacteremia in hospitalized patients. Clin Infect Dis 
2012 Jun;54;12:1692-8. 
 12.  Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset 
Escherichia coli bacteremia in seniors. J Infect Dis 2005 May 1;191;9:1523-9. 
 13.  Public Health England. Management of infection guidance for primary care for consulation and 
local adaptation. GOV UK 2014Available from: URL: 
21 
 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/377509/PHE
_Primary_Care_guidance_14_11_14.pdf 
 14.  Health Protection Agency. English National Point Prevalence Survey on Healthcare-associated 
Infections and Antimicrobial Use, 2011. GOV UK 2015 [cited 2015 May 29];Available from: 
URL: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/331871/Eng
lish_National_Point_Prevalence_Survey_on_Healthcare_associated_Infections_and_Antimicro
bial_Use_2011.pdf 
 15.  National Institute for Health and Care Excellence. Three-days courses of antibiotics for 
uncomplicated urinary tract infection. NICE website 2015 [cited 2015 Nov 3];Available from: 
URL: https://www.nice.org.uk/advice/ktt10/resources/threeday-courses-of-antibiotics-for-
uncomplicated-urinary-tract-infection-58757946016453 
 16.  Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary 
care on antimicrobial resistance in individual patients: systematic review and meta-analysis. 
BMJ 2010;340:c2096. 
 17.  Health Protection Agency, British Infection Association. Diagnosis of UTI. Quick Reference 
Guide for Primary Care. GOV UK website 2015 [cited 2015 Jun 2];Available from: URL: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/345784/UTI
_quick_ref_guidelines.pdf 
 18.  Royal Colleage of Nursing. Catheter Care. RCN Guidance for Nurses. London: Royal College of 
Nursing; 2012.  
 19.  Barbadoro P, Labricciosa FM, Recanatini C, Gori G, Tirabassi F, Martini E, et al. Catheter-
associated urinary tract infection: Role of the setting of catheter insertion. Am J Infect Control 
2015 Mar 31. 
 20.  National Institute for Health and Care Excellence. Long term urinary catheters: prevention and 
control of healthcare-associated infections in primary and community care. NICE website 2015 
[cited 2015 Nov 3];Available from: URL: http://pathways.nice.org.uk/pathways/prevention-
and-control-of-healthcare-associated-infections/prevention-and-control-of-healthcare-
associated-infections-in-secondary-care#path=view%3A/pathways/prevention-and-control-of-
healthcare-associated-infections/long-term-urinary-catheters-prevention-and-control-of-
healthcare-associated-infections-in-primary-and-community-care.xml&content=view-index 
 21.  McNulty CAM, Verlander NK, Turner K, Fry C. Point prevalence survey of urinary 
catheterisation in care homes and where they were inserted, 2012. Journal of Infection 
Prevention 2014;15;4:122-6. 
 22.  Rebmann T, Greene LR. Preventing catheter-associated urinary tract infections: An executive 
summary of the Association for Professionals in Infection Control and Epidemiology, Inc, 
Elimination Guide. Am J Infect Control 2010 Oct;38;8:644-6. 
 23.  Fakih MG, Shemes SP, Pena ME, Dyc N, Rey JE, Szpunar SM, et al. Urinary catheters in the 
emergency department: very elderly women are at high risk for unnecessary utilization. Am J 
Infect Control 2010 Nov;38;9:683-8. 
22 
 
 24.  Bruminhent J, Keegan M, Lakhani A, Roberts IM, Passalacqua J. Effectiveness of a simple 
intervention for prevention of catheter-associated urinary tract infections in a community 
teaching hospital. Am J Infect Control 2010 Nov;38;9:689-93. 
 25.  Parry MF, Grant B, Sestovic M. Successful reduction in catheter-associated urinary tract 
infections: Focus on nurse-directed catheter removal. Am J Infect Control 2013 
Dec;41;12:1178-81. 
 26.  Marra AR, Sampaio Camargo TZ, Goncalves P, Sogayar AM, Moura DF, Jr., Guastelli LR, et al. 
Preventing catheter-associated urinary tract infection in the zero-tolerance era. Am J Infect 
Control 2011 Dec;39;10:817-22. 
 
 
